Insider Selling: Alignment Healthcare (NASDAQ:ALHC) Insider Sells 18,404 Shares of Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Hyong Kim sold 18,404 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $17.84, for a total value of $328,327.36. Following the transaction, the insider owned 367,701 shares of the company’s stock, valued at $6,559,785.84. This trade represents a 4.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Hyong Kim also recently made the following trade(s):

• On Tuesday, January 6th, Hyong Kim sold 16,506 shares of Alignment Healthcare stock. The shares were sold at an average price of $21.35, for a total value of $352,403.10.
• On Monday, December 29th, Hyong Kim sold 12,694 shares of Alignment Healthcare stock. The shares were sold at an average price of $18.74, for a total transaction of $237,885.56.

Alignment Healthcare Trading Down 0.2%

Alignment Healthcare stock traded down $0.03 during mid-day trading on Thursday, hitting $18.16. 3,987,587 shares of the stock were exchanged, compared to its average volume of 3,191,394. The company has a quick ratio of 1.71, a current ratio of 1.71 and a debt-to-equity ratio of 1.80. Alignment Healthcare, Inc. has a 12 month low of $11.63 and a 12 month high of $23.87. The firm’s fifty day simple moving average is $20.57 and its two-hundred day simple moving average is $18.78.

Alignment Healthcare (NASDAQ:ALHC) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.10. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.49%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same period in the prior year, the firm posted ($0.16) EPS. The company’s quarterly revenue was up 44.4% on a year-over-year basis. As a group, equities analysts predict that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current year.

Key Stories Impacting Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Recent analyst upgrades/price-target raises provide near-term support (UBS raised target to $21, Piper Sandler to $30, JPMorgan to $26), and the consensus target remains above the current price—helping underpin valuation.
• Positive Sentiment: Solid quarterly results: February quarter beat EPS and revenue estimates (revenue +44% YoY; EPS beat by $0.10), showing growth momentum in Medicare Advantage enrollment and monetization that supports longer-term upside.
• Neutral Sentiment: Zacks ran a comparison piece weighing ALHC vs. BrightSpring (BTSG) for value investors — useful context but not a company-specific catalyst. BTSG or ALHC: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Reported short-interest data is effectively zero/NaN in the recent reports (likely a reporting quirk); it doesn’t indicate a build of short pressure currently.
• Negative Sentiment: Cluster of insider sales from senior executives — President Dawn Maroney sold 30,000 shares (~$524k at $17.48) and other officers (Andreas P. Wagner, Robert L. Scavo) sold sizable blocks (~11k–12k shares each). Heavy insider selling can signal liquidity needs or personal diversification and often weighs on sentiment. Maroney sale filing: Maroney Form 4
• Negative Sentiment: Additional insider filings: Andreas P. Wagner sales (Form 4) and Robert L. Scavo sale (Form 4) were also disclosed, adding to the headline of insider liquidation. Wagner filing: Wagner Form 4 · Scavo filing: Scavo Form 4
• Negative Sentiment: Independent sell-side views: Weiss Ratings reiterated a “sell (D-)” and Wall Street Zen trimmed its rating to a hold — these dissenting views add downside risk if they influence broader investor sentiment. Weiss Ratings · Wall Street Zen reference included in company coverage.

Hedge Funds Weigh In On Alignment Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada grew its stake in shares of Alignment Healthcare by 92.6% in the 1st quarter. Royal Bank of Canada now owns 92,379 shares of the company’s stock valued at $1,720,000 after buying an additional 44,413 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Alignment Healthcare by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company’s stock worth $1,109,000 after buying an additional 2,594 shares during the period. Goldman Sachs Group Inc. raised its stake in Alignment Healthcare by 79.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company’s stock worth $18,112,000 after buying an additional 429,703 shares during the period. Woodline Partners LP bought a new position in Alignment Healthcare in the first quarter worth approximately $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Alignment Healthcare by 16.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company’s stock valued at $5,729,000 after acquiring an additional 44,452 shares during the period. Institutional investors own 86.19% of the company’s stock.

Analyst Upgrades and Downgrades

ALHC has been the subject of several research analyst reports. Piper Sandler lifted their price objective on Alignment Healthcare from $20.00 to $30.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 6th. Robert W. Baird set a $28.00 target price on Alignment Healthcare in a research report on Friday, January 30th. KeyCorp reaffirmed an “overweight” rating and set a $28.00 target price on shares of Alignment Healthcare in a research note on Thursday, January 22nd. TD Cowen lifted their target price on Alignment Healthcare from $18.50 to $25.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Finally, Wall Street Zen cut Alignment Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.56.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.